• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Hua Medicine

Monday, June 03, 2024
Metabolic Diseases
Company Presentation Theater 2
Hua Medicine is a publicly traded biotechnology company, listed on the Hong Kong Stock Exchange (ticker: 2552) and headquartered in Shanghai, China. Hua is principally focused on curing Type 2 diabetes by restoring the body's natural ability to maintain glucose homeostasis on its own. This autonomous ability to maintain glucose homeostasis is impaired due to the deterioration of the function of the glucose sensing enzyme in the body, glucokinase (GK), located principally in the pancreatic beta-cells and intestines. In-licensed from Roche as pre-clinical compound, Hua has developed dorzagliatin, a GK activator (GKA), into a commercialized medicine approved and reimbursed in China - the only global first-in-class GKA. After the conclusion of one of its Ph3 registration trial, an ~65% diabetes remission rate over a subsequent drug-free 52-week period was observed, the results of which were published in Diabetes, Obesity and Metabolism in 2023.
Hua Medicine
Company Website: https://www.huamedicine.com/En
Lead Product in Development: Dorzagliatin, marketed as HuaTangNing in China
Number Of Unlicensed Products (For Which You Are Seeking Partners): 5

Exchange

Hong Kong Stock Exchange

Ticker

2552

Company HQ City

Shanghai

Company HQ State

Shanghai

Company HQ Country

China

CEO/Top Company Official

Dr. Li CHEN

Development Phase of Primary Product

Multiple Products in Market
Primary Speaker
George Lin, JD
EVP & Chief Strategy Officer
Hua Medicine
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS